Biotech fundraising boom continues with CureVac IPO
Germany’s CureVac has gone public on the Nasdaq, joining the army of biotech companies that have tapped the equity capital markets for cash during the pandemic, despite growing concern of a brewing dot-com style bubble.
CureVac sold 13.33m shares at $16 each, the top of the range, raising $213m. The company will be valued at $2.7bn when it starts trading in New York on Friday morning.
If the greenshoe is used, the size of the IPO could grow to $245mBerenberg, Bank of ...